-
Mashup Score: 6Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline† - 2 year(s) ago
Hereditary breast and ovarian cancer syndrome (HBOC) is clinically defined by family history criteria, and molecularly defined by identification of germline pathogenic variants (PVs) in clinically validated HBOC genes.1 These genes are broadly classified as high-risk genes, increasing breast and/or tubo-ovarian cancer risk by at least fourfold, and moderate-risk genes, increasing risk by two- to…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Online in @Annals_Oncology updated @myESMO guidelines on risk reduction and screening of #cancer in hereditary breast-ovarian cancer syndromes: honored to be part of this important work! @OncoAlert @UniGenova @SanMartino_Ge #UNIGEnonsiferma #bcsm #BRCA https://t.co/bsY9DVxFL3
-
-
Mashup Score: 15Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy - 2 year(s) ago
AbstractBackground. Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on th
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
Out in @JNCI_Now our #APHINITY analysis showing no negative impact of young age at #BreastCancer diagnosis on clinical outcomes & efficacy of adjuvant dual anti-#HER2 targeted therapy @OncoAlert @AnnPartridgeMD @E_de_Azambuja @BIGagainstBC #UNIGEnonsiferma https://t.co/PYXIT0WGzW
-
-
Mashup Score: 4
AbstractSTUDY QUESTION. Is it safe to perform controlled ovarian stimulation (COS) for fertility preservation before starting anticancer therapies or ART after
Source: OUP AcademicCategories: Latest Headlines, Oncologists1Tweet-
So proud to share the latest work led by my friend @Lucarecco fellow at @UniGenova @SanMartino_Ge online in @ESHRE @OUPMedicine journal #HumReprod: #fertility preservation is safe in young #BreastCancer patients @OncoAlert #UNIGEnonsiferma #SurvOnc #bcsm https://t.co/XVr1LOkyKi https://t.co/U7ItcrFWki
-
-
Mashup Score: 7
Purpose As a further step to elucidate the actual diverse spectrum of oncofertility practices for breast cancer around the globe, we present and discuss the comparisons of oncofertility practices for breast cancer in limited versus optimum resource settings based on data collected in the Repro-Can-OPEN Study Part I & II. Methods We surveyed 39 oncofertility centers including 14 in limited…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
Another study this week to highlight the importance of improving #oncofertility practices for #BreastCancer in limited resource setting: honored to be part of the @oncofertility consortium ! #UNIGEnonsiferma @OncoAlert #bcsm @SpringerNature #JARG Link: https://t.co/P2FfUR4tZE https://t.co/H94yuvucCI
-
-
Mashup Score: 8
PURPOSE Fertility and pregnancy-related issues are highly relevant for young (≤ 40 years) patients with breast cancer. Limited evidence exists on knowledge, practice, and attitudes of physicians from low- and middle-income countries (LMICs) regarding these issues. METHODS A 19-item questionnaire adapted from an international survey exploring issues about fertility preservation and pregnancy after…
Source: JCO Global OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Out in @JCOGO_ASCO our large global survey investigating physicians awareness and education in the #oncofertility field for #BreastCancer patients: congrats @SZK_ONCO @M_Tagliamento et al @OncoAlert @UniGenova @SanMartino_Ge #UNIGEnonsiferma #bcsm @ASCO https://t.co/IPHcMJRQTs https://t.co/R0i8dsX1fI
-
-
Mashup Score: 2
Purpose Accurate diagnosis and prediction of loss of ovarian function after chemotherapy for premenopausal women with early breast cancer (eBC) is important for future fertility and clinical decisions regarding the need for subsequent adjuvant ovarian suppression. We have investigated the value of anti-mullerian hormone (AMH) as serum biomarker for this. Methods AMH was measured in serial blood…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
Starting 2022 with clinically relevant data for #EndocrineTherapy choices in premenopausal early #BreastCancer patients aged 40-45: #AMH may be a reliable diagnostic test for lack of ovarian function after #chemotherapy @OncoAlert #UNIGEnonsiferma #bcsm https://t.co/7QqLglJm6c https://t.co/y9tkWajZMD
-
-
Mashup Score: 3Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate - 2 year(s) ago
Neoadjuvant chemotherapy is the recommended approach for patients with triple-negative breast cancer (TNBC) with clinically node-positive and/or tumors >1 cm.1 The addition of a platinum agent to standard neoadjuvant anthracycline- and taxane-based chemotherapy is debated. Our previous meta-analysis including 2109 patients from nine randomized, controlled trials (RCTs) reported a significant…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Here the link for 50 days' free access to our updated meta-analysis led by @Poggio_Fra out in @Annals_Oncology on platinum-based #chemotherapy in early triple-negative #BreastCancer #UNIGEnonsiferma #TNBC #bcsm @OncoAlert @UniGenova @SanMartino_Ge https://t.co/mhmaZdsAMP https://t.co/DvPUIHGGF9
-
-
Mashup Score: 1Immunotherapy for cancer treatment during pregnancy - 2 year(s) ago
Immunotherapy has greatly improved outcomes for subgroups of patients with cancer. As indications keep expanding, there is an unmet need to gain a bet…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists1Tweet-
Extensive review on #immunotherapy for #cancer treatment during #pregnancy just out in @TheLancetOncol: crucial issue, so grateful for the chance to contribute! Free download here: https://t.co/uWrs9fznDz @OncoAlert #UNIGEnonsiferma @UniGenova @SanMartino_Ge @HaanenJohn #IO https://t.co/Edomqskiy3
-
-
Mashup Score: 1
Immune checkpoint inhibitors (ICIs) have revolutionised clinical practice in oncology in the last years, leading to a survival benefit in several tumour types. To investigate whether these benefits are associated with improved quality of life, we conducted a systematic review and meta-analysis comparing patient-reported outcomes (PROs) between ICIs and standard chemotherapy (CT) in patients with…
Source: European Journal of CancerCategories: Latest Headlines, Oncologists1Tweet-
RT @Lucarecco: ➡️ https://t.co/zKI1rhIuiT @OncoAlert @myESMO @ONcotwITting @UniGenova @SanMartino_Ge #unigenonsiferma
-
Great updated review article on #oncofertility just out in @CBCjournal by @MRazeti & @UniGenova @SanMartino_Ge team: hope it can help improving the counseling of young #BreastCancer patients Free download for 50 days: https://t.co/nAUGqBTn17 @OncoAlert #UNIGEnonsiferma #bcsm https://t.co/56j8AKcOgB